Gackenheimer S L, Suter T M, Pintar J E, Quimby S J, Wheeler W J, Mitch C H, Gehlert D R, Statnick M A
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
Neuropeptides. 2005 Dec;39(6):559-67. doi: 10.1016/j.npep.2005.09.006. Epub 2005 Nov 9.
Agonist stimulation of opioid receptors increases feeding in rodents, while opioid antagonists inhibit food intake. The pan-opioid antagonist, LY255582, produces a sustained reduction in food intake and body weight in rodent models of obesity. However, the specific receptor subtype(s) responsible for this activity is unknown. To better characterize the pharmacology of LY255582, we examined the binding of a radiolabeled version of the molecule, [(3)H]-LY255582, in mouse brain using autoradiography. In mouse brain homogenates, the K(d) and B(max) for [(3)H]-LY255582 were 0.156 +/- 0.07 nM and 249 +/- 14 fmol/mg protein, respectively. [(3)H]-LY255582 bound to slide mounted sections of mouse brain with high affinity and low non-specific binding. High levels of binding were seen in areas consistent with the known localization of opioid receptors. These areas included the caudate putamen, nucleus accumbens, claustrum, medial habenula, dorsal endopiriform nucleus, basolateral nucleus of the amygdala, hypothalamus, thalamus and ventral tegmental area. We compared the binding distribution of [(3)H]-LY255582 to the opioid receptor antagonist radioligands [(3)H]-naloxone (mu), [(3)H]-naltrindole (delta) and [(3)H]-norBNI (kappa). The overall distribution of [(3)H]-LY255582 binding sites was similar to that of the other ligands. No specific [(3)H]-LY255582 binding was noted in sections of mu-, delta- and kappa-receptor combinatorial knockout mice. Therefore, it is likely that LY255582 produces its effects on feeding and body weight gain through a combination of mu-, delta- and kappa-receptor activity.
阿片受体的激动剂刺激会增加啮齿动物的进食量,而阿片拮抗剂则会抑制食物摄入。泛阿片拮抗剂LY255582在肥胖啮齿动物模型中能持续降低食物摄入量和体重。然而,负责此活性的具体受体亚型尚不清楚。为了更好地表征LY255582的药理学特性,我们使用放射自显影术研究了该分子的放射性标记版本[³H]-LY255582在小鼠脑中的结合情况。在小鼠脑匀浆中,[³H]-LY255582的解离常数(K(d))和最大结合容量(B(max))分别为0.156±0.07 nM和249±14 fmol/mg蛋白质。[³H]-LY255582以高亲和力和低非特异性结合与小鼠脑的载玻片切片结合。在与阿片受体已知定位一致的区域观察到高水平的结合。这些区域包括尾状壳核、伏隔核、屏状核、内侧缰核、背内侧梨状核、杏仁核基底外侧核、下丘脑、丘脑和腹侧被盖区。我们将[³H]-LY255582的结合分布与阿片受体拮抗剂放射性配体[³H]-纳洛酮(μ)、[³H]-纳曲吲哚(δ)和[³H]-去甲苄吗啡(κ)进行了比较。[³H]-LY255582结合位点的总体分布与其他配体相似。在μ、δ和κ受体组合敲除小鼠的切片中未观察到特异性的[³H]-LY255582结合。因此,LY255582可能通过μ、δ和κ受体活性的组合对进食和体重增加产生影响。